Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefotaxime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 2/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.86 |
| ▸ | APEX1 | P27695 | 3/20 | 0.86 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | PKM | P14618 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.86 |
| ▸ | POLB | P06746 | 1/20 | 0.86 |
| ▸ | RECQL | P46063 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefotaxime SCHEMBL10748430 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL17422140 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL2220120 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL1583477 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL10337429 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL3731937 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL3731931 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL5441797 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL9682785 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 | |
| Cefotaxime SCHEMBL16072837 | 1.00 | NR1I2 (1.00) | NR1I2MAPTPPARGSLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 45953 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122071712-A | Beta-lactam antibiotic whole-cell biosensor, construction method and application | 中国科学院天津工业生物技术研究所 | 2026-05-22 | — | — | CN | claimed |
| WO-2026104587-A1 | CYCLIC BORONIC ACID ESTERS USEFUL AS ADJUVANTS IN THE TREATMENT OF BACTERIAL INFECTIONS | ADJUTEC PHARMA AS (NO) | 2026-05-21 | — | — | WO | claimed |
| EP-4743580-A1 | EFFICIENT TRANSGENE-FREE GENOME EDITING IN PLANTS IN THE T0 GENERATION BASED ON A CO-EDITING STRATEGY | University of Florida Research Foundation, Incorporated (US) | 2026-05-20 | — | — | EP | claimed |
| CN-115215923-B | Macrocyclic broad-spectrum antibiotics | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-118304316-B | Application of cladribine in preparation of drug for inhibiting growth of multi-drug resistant klebsiella pneumoniae | 华南农业大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122036889-A | Cyclized antibacterial peptide CycP-1 of targeted multi-drug resistant klebsiella pneumoniae, composition and application thereof | 湖北江夏实验室 | 2026-05-15 | — | — | CN | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | claimed |
| US-12622919-B2 | Methods for treating hypervirulent Klebsiella pneumoniae infection | CITY UNIVERSITY OF HONG KONG (CN) | 2026-05-12 | — | — | US | claimed |
| EP-4736859-A1 | ANTIBIOTIC COMPOSITIONS | University of Galway (IE) | 2026-05-06 | — | — | EP | claimed |
| EP-0084925-A1 | 6-Aminoalkylpenicillanic acid 1,1-dioxides and derivatives as beta-lactamase inhibitors | PFIZER INC. (US) | 1983-08-03 | — | — | EP | claimed |
| EP-0083977-A1 | 6-Alpha-hydroxymethylpenicillanic acid sulfone as a beta-lactamase inhibitor | PFIZER INC. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0074783-A1 | Beta-lactamase inhibiting 2-beta-substituted-2-alpha-methyl-(5R) penam-3-alpha-carboxylic acid 1,1-dioxides and intermediates therefor | PFIZER INC. (US) | 1983-03-23 | — | — | EP | claimed |
| WO-1982003090-A1 | METHOD AND KIT FOR IDENTIFICATION OF BETA-LACTAMASES | JAMES RICHARD | 1982-09-16 | — | — | WO | claimed |
| EP-0059645-A1 | Method and kit for identification of beta-lactamases | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1982-09-08 | — | — | EP | claimed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4256733-A | Acetoxymethyl penam compounds as β-lactamase inhibitors | PFIZER INC. (US) | 1981-03-17 | — | — | US | claimed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | claimed |